Literature DB >> 9916306

Optimisation and routine use of generic ultra-high flow-rate liquid chromatography with mass spectrometric detection for the direct on-line analysis of pharmaceuticals in plasma.

J Ayrton1, G J Dear, W J Leavens, D N Mallett, R S Plumb.   

Abstract

The use of ultra-high flow-rate chromatography coupled to mass spectrometry offers great potential for the rapid, on-line analysis of pharmaceutical compounds in plasma as it permits high throughput direct analysis of plasma samples without any time-consuming sample preparation such as solid-phase extraction. The coupling of mass spectrometry with high-performance liquid chromatography often results in enhanced selectivity and sensitivity compared to, for example, ultraviolet absorbance detection. This can remove the need for complete resolution of the analyte from endogenous materials in the matrix. The use of large particle size stationary phases, and therefore, the ability to use large porosity column end frits, coupled with the added selectivity and sensitivity of the mass spectrometer allows an on-line analysis approach to be used for the direct analysis of pharmaceuticals in biological matrices with extremely high throughput. This paper presents an overview of the manner in which we have optimised this technique for the analysis of plasma samples, in terms of gradient profile, system configuration and optimal injection volume for maximum throughput and robustness. The nature of the mobile phase flow is also discussed.

Mesh:

Substances:

Year:  1998        PMID: 9916306     DOI: 10.1016/s0021-9673(98)00579-2

Source DB:  PubMed          Journal:  J Chromatogr A        ISSN: 0021-9673            Impact factor:   4.759


  2 in total

1.  Application of parallel liquid chromatography/mass spectrometry for high throughput microsomal stability screening of compound libraries.

Authors:  Rongda Xu; Csaba Nemes; Kelly M Jenkins; Robyn A Rourick; Daniel B Kassel; Charles Z C Liu
Journal:  J Am Soc Mass Spectrom       Date:  2002-02       Impact factor: 3.109

2.  Case Study 9: Probe-Dependent Binding Explains Lack of CYP2C9 Inactivation by 1-Aminobenzotriazole (ABT).

Authors:  Jasleen K Sodhi; Jason S Halladay
Journal:  Methods Mol Biol       Date:  2021
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.